Benefits of ECpella - Therapy Options for Cardiogenic Shock Patients
Cardiogenic shock patients need advanced therapies that provide oxygenation and full cardiac support. Learn more about the benefits of the ECpella therapy.
Early Left Ventricular Unloading Improves Survival in Patients in Cardiogenic Shock
Supported by Extracorporeal Membrane Oxygenation (ECMO)
New research shows that early left ventricular unloading with Impella heart pumps improves survival in patients with cardiogenic shock supported by extracorporeal membrane oxygenation (ECMO) - learn more in the interview with Dr. Benedikt Schrage.
New Therapeutic Concepts of Combining ECLS With Impella Heart Pumps in Cardiogenic Shock
Dr. Armin Klesius interviews Prof. Evgenij Potapov on new therapeutic concepts in the field of ECpella therapy.
ECMO-CS Trial: VA ECMO in Rapidly Deteriorating or Severe Cardiogenic Shock
Jan Belohlavek, MD, PhD, discusses results from the ECMO-CS trial that he and his colleagues recently published in Circulation.
ELSO 2022 Q&A with Evgenij Potapov, Roberto Lorusso, and Alan Gass
In this Q&A session from the Extracorporeal Life Support Organization (ELSO) meeting in 2022 the attendees discuss the importance of LV unloading for heart recovery and other aspects of managing ECpella patients.
85% Survival with ECpella Approach Using the Impella 5.5® with SmartAssist® Heart Pump
Alan Gass, MD, discusses data he has published on the use of Impella 5.5® with SmartAssist® heart pump in patients with SCAI Stages D and E cardiogenic shock.
Improving Survival in Cardiogenic Shock —
A Propensity Score-Matched Analysis of the Impact of an Institutional Allocation Protocol to Short-Term Mechanical Circulatory Support
In this paper, Sascha Ott, Daniel Lewin, Gaik Nersesian, et al. describe a standard operating procedure (SOP) they developed for determining the temporary mechanical circulatory support (tMCS) strategy for patients in cardiogenic shock (CS).
- Schrage et al :Timing of Active LV Unloading in VA-ECMO. JACC : HeartFailure V O L . -, NO. -, 2022.